Hemoglobinopathies Market

1. Hemoglobinopathies Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast The global hemoglobinopathies market size was USD 7.1 billion in 2020 and is anticipated to reach USD 15.7 billion by 2028, expanding at a CAGR of 10.8 % during the forecast period, 2021–2028. The growth of the market is attributed to the increasing prevalence of diseases, including sickle cell disease (SCD) and thalassemia. Furthermore, the presence of a robust product pipeline for hemoglobinopathies treatment is driving the market growth. Hemoglobinopathy is a group of hereditary illnesses caused by aberrant hemoglobin production or structural abnormalities. Sickle cell anemia, hemoglobin S-C disease, and thalassemia are among the numerous ailments of illness. The group of disorders earlier found in Mediterranean region and huge parts of Asia and Africa, have been widespread across the world due to increased migration. According to a survey issued by the American Society of Hematology, more than 95 percent of infants born with thalassemia are from low- and middle-income nations, with less than 5% living in North America and Europe. In low-income nations, lack of awareness and high unmet requirements linked to diagnosis and treatment are two main factors contributing to the prevalence of disorders. Around 4.4 out of every 10,000 live births worldwide are affected with thalassemia. According to the World Health Organization (WHO), about 330,000 newborns are born each year with hemoglobin abnormalities. As per the Centers for Disease Control and Prevention (CDC), the incidence of sickle cell disease trait was determined to be 15.5 instances per 1,000 births in the US. Moreover, sickle cell trait affects 1.5 percent of newborns born in the country. SCD affects one out of every 365 Afro-American births in the US, but it affects one out of every 16,300 Hispanic-American birth. Market Trends, Drivers, Restraints, and Opportunities

2.  Increasing prevalence of hemoglobinopathies in developing and low-income countries is anticipated to boost the market growth during the forecast period. Lack of awareness, unmet requirements in the treatment of SCD and thalassemia, and absence of a permanent cure to these diseases are major factors contributing to the high frequency of hemoglobinopathies, spurring the growth of the market. Growing investment in the development of innovative medicines is expected to boost market growth. Several government programs such as thalassemia screening in neonates and the provision of treatments are projected to have a beneficial impact on market growth. Rising investment in the development of novel therapies is expected to drive the market growth during the forecast period. Increasing approvals from the regulatory bodies for novel therapies are expected to boost the market growth. For instance, Reblozyl, Adakveo, Zynteglo, and Oxbryta were approved by the food & drug administration (FDA) in 2019 for the treatment of hemoglobin problems.      Sample - https://growthmarketreports.com/request-sample/1928 Market Segment Insights Sickle cell segment is projected to account for a large market share Based on types, the market is divided into thalassemia, sickle cell disease, and other hemoglobin (Hb) variants. The thalassemia segment is further sub-segmented into alpha-thalassemia and beta- thalassemia. The sickle cell disease segment is expected to account for a key market share during the forecast period owing to the expanding initiatives by biopharmaceutical companies and non-profit organizations at improve access to SCD treatment. Furthermore, SCD affects approximately 300,000 newborns each year. An estimated 10% to 40% of people in Africa are transmitters of the sickle cell gene. Over the forecast period, the rising global disease burden is expected to drive the market segment growth. Globally, approximately 5% of the total population is an alpha-thalassemia carrier and approximately 1.5 percent of the population has beta-thalassemia traits. India has the most thalassemia carriers in the world. Moreover, biopharmaceutical organizations are aggressively collaborating with each other to develop novel therapies for treating the disorder. For instance, CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated formed a partnership in December 2017 to develop and commercialize novel gene-editing treatments for thalassemia using CRISPR/Cas9 technology. Inquiry- https://growthmarketreports.com/enquiry-before-buying/1928 Competitive Landscape Key players competing in the hemoglobinopathies market are Sangamo Therapeutics, bluebird bio, Inc., Global Blood Therapeutics, Inc., Pfizer, Inc., Emmaus Life Sciences, Inc., Prolong Pharmaceuticals, LLC, Celgene Corporation, Bioverativ Inc., Gamida Cell, and Novartis AG. Market players are engaging in various initiatives such as mergers and acquisitions, partnerships, collaborations, and extensive R&D to expand their market share. For instance, Sangamo Therapeutics,

3. Inc., announced the acquisition of TxCell SA. The CAR-Treg platform, a proprietary technology developed by the company, has the potential to develop novel cell therapies for the treatment of autoimmune and inflammatory diseases. About Growth Market Reports: GMR provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Industry Intelligence Solutions”. GMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. Our key analysis segments, though not restricted to the same, include market entry strategies, market size estimations, market trend analysis, market opportunity analysis, market threat analysis, market growth/fall forecasting, primary interviews, secondary research & consumer surveys. Contact: Growth Market Reports Phone: +1 909 414 1393 Email: sales@growthmarketreports.com Web: https://growthmarketreports.com Follow Us: LinkedIn | Twitter